Distinguishing molecular markers in thyroid tumors: a tribute to Dr. Orlo Clark.

PubWeight™: 0.77‹?›

🔗 View Article (PMID 18784955)

Published in World J Surg on March 01, 2009

Authors

Martha A Zeiger1

Author Affiliations

1: Endocrine Surgery Section, Department of Surgery, Johns Hopkins Hospital, 600 N. Wolfe Street, Blalock 606, Baltimore, MD 21287, USA. mzeiger@jhmi.edu

Articles citing this

DNA copy number variations characterize benign and malignant thyroid tumors. J Clin Endocrinol Metab (2013) 0.79

Articles cited by this

High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res (2003) 8.67

BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab (2003) 4.93

PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science (2000) 3.87

Oncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis. Cancer Res (1989) 3.35

High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res (2003) 2.49

High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest (1993) 2.25

Thyroid nodules: clinical importance, assessment, and treatment. Endocrinol Metab Clin North Am (2007) 1.55

Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet (2001) 1.54

Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. J Clin Invest (1992) 1.52

Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules. Clin Cancer Res (2004) 1.47

Classification of follicular thyroid tumors by molecular signature: results of gene profiling. Clin Cancer Res (2003) 1.36

Implications of follicular neoplasms, atypia, and lesions suspicious for malignancy diagnosed by fine-needle aspiration of thyroid nodules. Ann Surg (2002) 1.32

Fine needle aspiration cytology of the thyroid, 1980 to 1986. Acta Cytol (1987) 1.27

A diagnostic predictor model for indeterminate or suspicious thyroid FNA samples. Thyroid (2008) 1.27

Follicular or Hürthle cell neoplasm of the thyroid: can clinical factors be used to predict carcinoma and determine extent of thyroidectomy? Surgery (1999) 1.24

Using gene expression profiling to differentiate benign versus malignant thyroid tumors. Cancer Res (2004) 1.21

Galectin-3 is a presurgical marker of human thyroid carcinoma. Cancer Res (1998) 1.18

Beyond the suspicious thyroid fine needle aspirate. A review. Acta Cytol (2003) 1.18

Discrimination of benign and malignant thyroid nodules by molecular profiling. Ann Surg (2004) 1.17

Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules. J Clin Endocrinol Metab (2004) 1.15

Diagnosis of suspicious thyroid nodules using four protein biomarkers. Clin Cancer Res (2006) 1.07

Identification of genes differentially expressed in benign versus malignant thyroid tumors. Clin Cancer Res (2008) 1.05

Evaluation and management of the solid thyroid nodule. Endocrinol Metab Clin North Am (1995) 1.05

Thyroid cytology and the risk of malignancy in thyroid nodules: importance of nuclear atypia in indeterminate specimens. Thyroid (2001) 1.02

Molecular genetics of human thyroid neoplasms. Annu Rev Med (1994) 1.01

Papillary carcinoma of the thyroid: can operative management be based solely on fine-needle aspiration? J Am Coll Surg (1997) 1.00

Fine-needle aspiration biopsy of the thyroid. The problem of suspicious cytologic findings. Ann Intern Med (1984) 0.97

Genetic alterations in human epithelial thyroid tumours. Clin Endocrinol (Oxf) (1998) 0.94

Perspective: lessons learned from molecular genetic studies of thyroid cancer--insights into pathogenesis and tumor-specific therapeutic targets. Endocrinology (2002) 0.92

Galectin-3, a marker of well-differentiated thyroid carcinoma, is expressed in thyroid nodules with cytological atypia. Histopathology (2002) 0.91

Molecular genetics of thyroid tumors and surgical decision-making. World J Surg (2000) 0.89

A six-gene model for differentiating benign from malignant thyroid tumors on the basis of gene expression. Surgery (2005) 0.89

Microarray analysis of thyroid nodule fine-needle aspirates accurately classifies benign and malignant lesions. J Mol Diagn (2006) 0.88

Follicular thyroid lesions, elements that affect both diagnosis and prognosis. J Surg Oncol (2005) 0.88

Molecular analysis of minimally invasive follicular carcinomas by gene profiling. Surgery (2005) 0.88

Galectin-3 and CD44v6 isoforms in the preoperative evaluation of thyroid nodules. J Clin Oncol (1999) 0.87

Identification of candidates for tumor-specific alternative splicing in the thyroid. Genes Chromosomes Cancer (2006) 0.85

Thyroid-specific expression of cholera toxin A1 subunit causes thyroid hyperplasia and hyperthyroidism in transgenic mice. Endocrinology (1997) 0.82

Molecular basis of epithelial tumorigenesis: the thyroid model. Crit Rev Oncog (1993) 0.81

Inverse association between cyclin D1 overexpression and retinoblastoma gene mutation in thyroid carcinomas. Endocrine (1998) 0.80

Molecular pathogenesis of thyroid nodules and cancer. Baillieres Best Pract Res Clin Endocrinol Metab (2000) 0.80

Gene rearrangements in radiation-induced thyroid carcinogenesis. Med Pediatr Oncol (2001) 0.80

Utilization of fine-needle aspiration in patients undergoing thyroidectomy at two academic centers across the Atlantic. World J Surg (2003) 0.77

An in vitro model of thyroid neoplasia: permanently transfected FRTL-5 cells with thyroglobulin promoter-cholera toxin A1 subunit minigene. Surgery (1994) 0.75